About this event
The molecular profiling of cancer has enabled deeper insights into the complexity of cancer. From the development of the first targeted cancer therapy, to understanding cancer risk and putting in preventative measures, being able to tailor the cancer treatment pathway to an individual based on their molecular information holds a lot of promise for better outcomes.
However, a lot of a challenges remain with realising the dream of precision oncology. Among the challenges include the development and refinement of informative biomarkers, data interpretation and actionability.
Join us for this unique series: Precision Oncology ONLINE as we address the challenges associated with turning cancer research into the next era of cancer care.
14th October, 3pm BST/ 4pm CEST/ 10am EDT
The development of diagnostic assays and biomarkers that can be used in the clinical setting will transform the way molecular information is gathered and utilised in the patient cancer journey. This webinar will focus on research that advances diagnostics and biomarker development for precision oncology.
Cancer Biomarkers: unlocking the potential of Precision Oncology for patients and for health systems – Mark Lawler, Chair in Translational Cancer Genomics, Queen’s University Belfast
When tissue is an issue: urine as a liquid biopsy in oncology screening - Stephanie Jordaens, Biomedical Scientist, Novosanis and PhD student, University of Antwerp
Colorectal cancer – novel insights and opportunities to overcome therapy resistance – Andrew Beggs, Professor of Translational Genomics, University of Birmingham
Other webinars in the series:
7th October, 3pm BST/ 4pm CEST/ 10am EDT
With the ongoing research into the omics of cancer, our understanding is rapidly developing. However, the translation of these findings into the clinic is slow. This webinar will focus on how the molecular characterisation of tumours can translate into advances in the clinical management of cancers and bring us closer to the promise of precision oncology.
Precision Oncology – Opportunities and challenges - Benedikt Westphalen, Medical Lead Precision Oncology, Munich Comprehensive Cancer Centre
Getting the right answers for Precision Oncology with the new SureSelect All Human Exome V8 - Edward Jan, Sr. Global Product Manager, NGS, Diagnostics and Genomics Group, Agilent Technologies
Molecular therapies and Precision Medicine for cholangiocarcinoma– Daniela Sia, Assistant Professor, Mount Sinai Liver Cancer Program
21st October, 3pm BST/ 4pm CEST/ 10am EDT
This webinar will address the challenges that are associated with implementing precision medicine and evaluate whether we are delivering on the promise of precision oncology, and if not, how can we?
How next-generation diagnostics empower precision medicine in leukemia – Torsten Haferlach, CEO, Munich Leukaemia Laboratory
Cancer diagnosis – the future? – Richard Roope, Clinician advisor, CRUK
Harnessing genomics to drive change in personalised medicine - Deborah Lakeland, Cancer Genomics Project manager, Lancashire and South Cumbria Cancer Alliance
Front Line Genomics is a genomics-focused media company, with a social mission to deliver the benefits of genomics to patients faster. We organise the Festival of Genomics, digital events, reports, webinars and digital events, as well as operating a content-rich website.
Share this event